Skip to main content

Table 1 Baseline characteristics

From: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

 

Etanercept cohort (N = 2725)

Biologic-naïve cohort (N = 1517)

p†

Gender, female

1829 (67.1)

1023 (67.4)

0.8

Age at onset (years)

7.9 ± 4.7

7.7 ± 4.6

0.18

Age at baseline (years)

12.1 ± 4.4

9.8 ± 4.8

< 0.0001*

Disease duration (years)

4.1 ± 3.7

2.1 ± 2.8

< 0.0001*

JIA category

 Systemic JIA

146 (5.3)

58 (3.8)

0.025*

 RF-negative polyarthritis

904 (33.1)

415 (27.3)

< 0.0001*

 RF-positive polyarthritis

223 (8.1)

52 (3.4)

< 0.0001*

 Persistent oligoarthritis

120 (4.4)

390 (25.7)

< 0.0001*

 Extended oligoarthritis

570 (20.9)

204 (13.4)

< 0.0001*

 ERA

486 (17.8)

213 (14.0)

0.001*

 PsA

191 (7.0)

138 (9.0)

0.017*

 Unclassified JIA

85 (3.1)

47 (3.0)

1.0

ANA

1290 (47.3)

725 (47.8)

0.8

HLA-B27

643 (23.6)

265 (17.5)

< 0.0001*

Pretreatment at baseline

 NSAIDs

2478 (90.9)

1329 (87.6)

0.0007*

 Systemic steroids

1434 (52.6)

357 (23.5)

< 0.0001*

 MTX

2358 (86.5)

0 (0)

< 0.0001*

 Biologics

114 (4.2)

0 (0)

< 0.0001*

 Other DMARDs

1232 (45.2)

149 (9.8)

< 0.0001*

  SFZ

415 (15.2)

67 (4.4)

< 0.0001*

  HCQ

228 (8.4)

53 (3.5)

< 0.0001*

  AZA

237 (8.7)

14 (0.9)

< 0.0001*

  LEF

85 (3.1)

6 (0.4)

< 0.0001*

  CSA

140 (5.1)

8 (0.5)

< 0.0001*

  Chlorambucil

19 (0.7)

0 (0)

0.0004*

  Cyclophosphamide

10 (0.4)

0 (0)

0.0175*

  Gold salts

36 (1.3)

0 (0)

< 0.0001*

  Immunoglobulins

48 (1.8)

1 (0.1)

< 0.0001*

  MMF

14 (0.5)

0 (0)

0.0034*

Concomitant treatment at baseline

 NSAIDs

2158 (79.2)

360 (23.7)

0.0001*

 Systemic steroids

974 (35.7)

1394 (91.9)

0.0001*

 MTX

1867 (68.5)

1517 (100.0)

< 0.0001*

 Other DMARDs

  SFZ

145 (5.3)

36 (2.4)

0.0001*

  HCQ

37 (1.4)

14 (0.9)

0.24

  AZA

80 (2.9)

4 (0.3)

0.0001*

  LEF

59 (2.2)

1 (0.1)

0.0001*

  CSA

57 (2.1)

2 (0.1)

0.0001*

Disease activity parameters at baseline

 Active joints

6.7 ± 8.1

5.8 ± 7.6

0.0004*

 Swollen joints

5.3 ± 7.4

4.8 ± 6.8

0.03*

 Tender joints

6.5 ± 8.4

5.8 ± 7.8

0.007*

 PhysVAS

52.2 ± 32.3

47.2 ± 25.9

0.0001*

 PatVAS

43.7 ± 27.4

39.0 ± 26.0

0.0001*

 Joints with LOM

7.4 ± 8.9

5.7 ± 7.6

0.0001*

 CHAQ-DI

0.7 ± 0.6

0.6 ± 0.6

0.0001*

 ESR (mm/h)

23.5 ± 23.4

24.2 ± 23.0

0.35

 CRP (mg/L)

16.8 ± 32.7

13.9 ± 27.9

0.004*

 JADAS10

15.3 ± 7.5

13.9 ± 7.1

0.0001*

  1. Data are shown as n (%), mean ± SD, or n
  2. JIA juvenile idiopathic arthritis, RF rheumatoid factor, ERA enthesitis-related arthritis, PsA psoriatic arthritis, ANAs antinuclear antibodies, HLA human leucocyte antigen, NSAID nonsteroidal anti-inflammatory drug, MTX methotrexate, DMARD disease-modifying anti-rheumatic drug, SFZ sulfasalazine, HCQ hydroxychloroquine, AZA azathioprine, LEF leflunomide, CSA cyclosporine, PhysVAS physician global assessment of overall well-being, PatVAS parent/patient global assessment of overall well-being, LOM limitation of motion, CHAQ-DI Childhood Health Assessment Questionnaire disability index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADAS10 10-joint Juvenile Arthritis Disease Activity Score
  3. †By t test or Fisher’s exact test, as appropriate
  4. *p < 0.05
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us